Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area

NCT05266729 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate or Severe Submental Fullness

Interventions

DRUG: Polyene Phosphatidylcholine
DRUG: Placebo

Sponsor

AMIpharm Co., Ltd.